Harmony Biosciences price target raised to $59 from $56 at Oppenheimer
The Fly

Harmony Biosciences price target raised to $59 from $56 at Oppenheimer

Oppenheimer raised the firm’s price target on Harmony Biosciences (HRMY) to $59 from $56 and keeps an Outperform rating on the shares. The firm notes Harmony reported Q3 revenues of $186.0M, hitting its estimate and beating the Street’s $184.1M consensus. WAKIX’s momentum continues to impress Oppenheimer, with solid patient growth, expanding prescriber base, and robust coverage despite new/generic oxybate availability.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App